ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
120.767,19
-1,73%
S&P 500
5.346,99
-0,11%
US Dollar vs BRL
5,3461
1,66%
Bitcoin
69.367,64
-1,97%
Brent Oil
79,395
-0,61%
Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Relay Therapeutics Inc (RLAY)

  7. Relay Therapeutics Inc (RLAY) Notícias

RLAY

Relay Therapeutics (RLAY)

Relay Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:RLAY
DataHoraFonteTítuloCódigoCompanhia
06/06/202409:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RLAYRelay Therapeutics Inc
06/06/202408:00GlobeNewswire Inc.Relay Therapeutics Discloses Three New Programs at New Program & Platform EventNASDAQ:RLAYRelay Therapeutics Inc
05/06/202421:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RLAYRelay Therapeutics Inc
05/06/202417:12Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RLAYRelay Therapeutics Inc
05/06/202417:05GlobeNewswire Inc.Relay Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Atirmociclib in Combination with RLY-2608NASDAQ:RLAYRelay Therapeutics Inc
21/05/202417:05GlobeNewswire Inc.Relay Therapeutics to Participate in Upcoming Investor ConferencesNASDAQ:RLAYRelay Therapeutics Inc
13/05/202409:30GlobeNewswire Inc.Relay Therapeutics to Host New Program and Platform Event on June 6, 2024NASDAQ:RLAYRelay Therapeutics Inc
02/05/202417:05GlobeNewswire Inc.Relay Therapeutics Reports First Quarter 2024 Financial Results and Corporate HighlightsNASDAQ:RLAYRelay Therapeutics Inc
25/04/202417:05GlobeNewswire Inc.Relay Therapeutics to Announce First Quarter 2024 Financial Results and Corporate Highlights on May 2, 2024NASDAQ:RLAYRelay Therapeutics Inc
26/02/202418:05GlobeNewswire Inc.Relay Therapeutics to Participate in Three Upcoming Investor ConferencesNASDAQ:RLAYRelay Therapeutics Inc
22/02/202418:34Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:RLAYRelay Therapeutics Inc
22/02/202418:16Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:RLAYRelay Therapeutics Inc
22/02/202418:05GlobeNewswire Inc.Relay Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate HighlightsNASDAQ:RLAYRelay Therapeutics Inc
15/02/202418:05GlobeNewswire Inc.Relay Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights on February 22, 2024NASDAQ:RLAYRelay Therapeutics Inc
01/02/202418:05GlobeNewswire Inc.Relay Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceNASDAQ:RLAYRelay Therapeutics Inc
10/01/202411:22Edgar (US Regulatory)Form 424B7 - Prospectus [Rule 424(b)(7)]NASDAQ:RLAYRelay Therapeutics Inc
10/01/202411:14Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:RLAYRelay Therapeutics Inc
08/01/202409:00GlobeNewswire Inc.Relay Therapeutics Announces $30 Million Private Placement FinancingNASDAQ:RLAYRelay Therapeutics Inc
02/01/202418:05GlobeNewswire Inc.Relay Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:RLAYRelay Therapeutics Inc
07/11/202318:05GlobeNewswire Inc.Relay Therapeutics to Participate in Stifel 2023 Healthcare ConferenceNASDAQ:RLAYRelay Therapeutics Inc
02/11/202317:17Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:RLAYRelay Therapeutics Inc
02/11/202317:05GlobeNewswire Inc.Relay Therapeutics Reports Third Quarter 2023 Financial Results and Corporate HighlightsNASDAQ:RLAYRelay Therapeutics Inc
26/10/202317:05GlobeNewswire Inc.Relay Therapeutics to Announce Third Quarter 2023 Financial Results and Corporate Highlights on November 2, 2023NASDAQ:RLAYRelay Therapeutics Inc
12/10/202317:05GlobeNewswire Inc.Relay Therapeutics Announces Initial RLY-4008 (lirafugratinib) Data Demonstrating Durable Responses Across Multiple FGFR2-Altered Solid TumorsNASDAQ:RLAYRelay Therapeutics Inc
18/09/202317:05GlobeNewswire Inc.Relay Therapeutics to Present Clinical Data on RLY-4008 in Advanced FGFR2-Altered Solid Tumors at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsNASDAQ:RLAYRelay Therapeutics Inc
08/08/202317:02GlobeNewswire Inc.Relay Therapeutics Reports Second Quarter 2023 Financial Results and Corporate HighlightsNASDAQ:RLAYRelay Therapeutics Inc
01/08/202317:05GlobeNewswire Inc.Relay Therapeutics to Announce Second Quarter 2023 Financial Results and Corporate Highlights on August 8, 2023NASDAQ:RLAYRelay Therapeutics Inc
28/06/202318:13Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:RLAYRelay Therapeutics Inc
01/06/202319:22Edgar (US Regulatory)Amended Statement of Changes in Beneficial Ownership (4/a)NASDAQ:RLAYRelay Therapeutics Inc
31/05/202317:06Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:RLAYRelay Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:RLAY

Seu Histórico Recente

NASDAQ
VAGHX
Virtus Alphasimplex Mana...
EU
IOP6E
OSSIAM OP6E INAV
UNSW
KATETH
Kambria Token
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados